Get the Stockscreener App
17.71
0.34%
0.06
After Hours:
18.18
0.47
+2.65%
Oculis Holding Ag stock is traded at $17.71, with a volume of 5,906.
It is up +0.34% in the last 24 hours and down -8.90% over the past month.
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.
See More
Previous Close:
$17.65
Open:
$17.65
24h Volume:
5,906
Relative Volume:
0.25
Market Cap:
$773.26M
Revenue:
-
Net Income/Loss:
$-75.28M
P/E Ratio:
-8.8741
EPS:
-1.9957
Net Cash Flow:
$-57.45M
1W Performance:
+1.20%
1M Performance:
-8.90%
6M Performance:
-21.32%
1Y Performance:
+54.67%
1-Day Range:
$17.53
$18.03
1-Week Range:
$17.31
$18.15
52-Week Range:
$10.79
$23.08
Oculis Holding Ag Stock (OCS) Company Profile
Compare OCS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OCS
Oculis Holding Ag
|
17.71 | 900.74M | 0 | -75.28M | -57.45M | -1.9957 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Oculis Holding Ag Stock (OCS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-05-23 | Initiated | Chardan Capital Markets | Buy |
| Oct-05-23 | Initiated | Stifel | Buy |
| Jun-14-23 | Initiated | BofA Securities | Buy |
| Jun-12-23 | Initiated | H.C. Wainwright | Buy |
| Jun-08-23 | Initiated | Robert W. Baird | Outperform |
| May-10-23 | Initiated | Pareto | Buy |
| Apr-28-23 | Initiated | Wedbush | Outperform |
View All
Oculis Holding Ag Stock (OCS) Latest News
What analysts say about Oculis Holding AG Equity Warrant stockFree Buy/Sell Signal Notifications - PrintWeekIndia
Oculis Holding AG Stock Analysis and ForecastExplosive trading opportunities - PrintWeekIndia
Oculis Holding AG Equity Warrant Stock Analysis and ForecastOverwhelming profit margins - Autocar Professional
What drives Oculis Holding AG stock priceFree Stock Market Beginners Guide - PrintWeekIndia
What drives Oculis Holding AG Equity Warrant stock priceUnmatched profit growth - Autocar Professional
Is Oculis Holding AG a good long term investmentExplosive trading opportunities - Autocar Professional
Is Oculis Holding AG Equity Warrant a good long term investmentTremendous gains - jammulinksnews.com
When the Price of (OCSAW) Talks, People Listen - news.stocktradersdaily.com
What analysts say about Oculis Holding AG stockBreakout profit opportunities - Autocar Professional
Why Oculis Holding AG stock attracts strong analyst attentionMarket Timing Advice - Newser
Trend Tracker for (OCS) - news.stocktradersdaily.com
What analysts say about Oculis Holding AG Equity Warrant stock outlookPortfolio Boosting Stock Alerts - beatles.ru
How Oculis Holding AG Equity Warrant stock performs during market volatilityMomentum Swing Watchlist - Newser
How Oculis Holding AG stock performs during market volatilityFree Stock Selection - Newser
What makes Oculis Holding AG stock price move sharplyFree Best Stocks to Buy Today - Newser
Oculis Holding Ag Stock (OCS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.97%
0.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):